Oxford Pharmascience Group Plc Company Profile (LON:OXP)

Analyst Ratings

Consensus Ratings for Oxford Pharmascience Group Plc (LON:OXP) (?)
Ratings Breakdown: 1 Hold Rating(s)
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Oxford Pharmascience Group Plc (LON:OXP)
Show:
DateFirmActionRatingPrice TargetActions
7/21/2016Beaufort SecuritiesDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/25/2016N+1 SingerReiterated RatingCorporateView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/27/2014 forward)

Earnings

Earnings History for Oxford Pharmascience Group Plc (LON:OXP)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Oxford Pharmascience Group Plc (LON:OXP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Oxford Pharmascience Group Plc (LON:OXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Oxford Pharmascience Group Plc (LON:OXP)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Oxford Pharmascience Group Plc (LON:OXP)
DateHeadline
07/21/16 06:02 PMOxford Pharmascience : Seeks Partner For Bitter Pill Masking Platform
07/21/16 06:02 PMOxford Pharmascience Group ( OXP )
05/20/16 02:33 AMShares Magazine Investor Evening Presentation - [at noodls] - Oxford Pharmascience Group plc ('Oxford Pharmascience' or 'the Company') Presentation at the Shares Magazine Investor Evening (London) Oxford Pharmascience, the specialty pharmaceutical company that redevelops ...
04/22/16 06:25 AMOXP to exhibit at the Master Investor Show 2016 - [at noodls] - Oxford Pharmascience Group plc ('Oxford Pharmascience' or 'the Company') To exhibit at the Master Investor Show 2016 Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines ...
04/19/16 01:05 AMPositive Regulatory Advice from MHRA - [at noodls] - Oxford Pharmascience Group plc ('Oxford Pharmascience' or 'the Company') Oxford Pharmascience Announces on OXPzero NSAIDs programme Oxford Pharmascience, the specialty pharmaceutical company that redevelops ...
03/04/16 06:07 AMFull Year 2015 Oxford Pharmascience Group PLC Earnings Release - Time Not Supplied -
02/26/16 01:43 PMOxford Pharmascience : Adds Former Reckitt Director Sharma To Board - LONDON (Alliance News) - Oxford Pharmascience Group PLC on Thursday said it has appointed former Reckitt Benckiser Group PLC director Anand Sharma as a non-executive director. Sharma has worked in the pharmaceutical and consumer healthcare industry for ...
01/25/16 03:40 AMOxford Pharmascience Climbs on Search for Marketing Partner -
01/14/16 10:02 AMNaproxen Progresses into Proof of Concept Trials - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") 2nd OXPzeroTM NSAID molecule to enter PoC studies in man Oxford Pharmascience ...
01/14/16 10:02 AMNSAIDs Programme & Year End Financial Review - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ("Oxford Pharmascience" or the "Company") Update on NSAIDs Programme & Year End Financial Review NSAIDS Programme - Summary ...
01/14/16 10:02 AMSuccessful Pilot Clinical Study - [at noodls] - Oxford Pharmascience Group PLC of Immediate Release OXPzero™ Naproxen Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, ...
01/14/16 10:02 AMPK Results for OXPzero Naproxen vs. Naprosyn - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ('Oxford Pharmascience' or 'the Company') Pharmacokinetic (PK) Study Results for OXPzero™ Naproxen vs. Naprosyn® Oxford Pharmascience, the ...
01/14/16 10:02 AMIbuprofen progressing to proof of concept trial - [at noodls] - Oxford Pharmascience Group PLC Chewable Form of OXPzero™ Ibuprofen progressing to Proof-of-Concept Clinical Trial Oxford Pharmascience Group Plc (AIM: OXP), the specialty pharmaceutical company that redevelops ...
01/14/16 10:02 AMInitiation of Pilot Clinical Study for Naproxen - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ('Oxford Pharmascience' or the 'Company') Initiation of Pilot Clinical Study for Reduced Gastro-Intestinal Irritation Naproxen Oxford Pharmascience ...
01/14/16 10:02 AMProposed Placing - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc (the 'Company') Proposed £20 million Placing and Notice of General Meeting Oxford Pharmascience Group Plc (AIM: OXP), the specialty pharmaceutical ...
01/14/16 10:02 AMGrant of Share Options - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ('Oxford Pharmascience' or the 'Company') The Company today announces that, pursuant to the rules of the Company's Share Option Plan 2010, ...
01/14/16 10:02 AMPosting of Circular and Notice of GM - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ('Oxford Pharmascience' or the 'Company') Posting of Circular and Notice of General Meeting Further to the announcement of 2 June 2015, Oxford ...
01/14/16 10:02 AMResult of GM - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ('Oxford Pharmascience' or the 'Company') Result of AGM & General Meeting Oxford Pharmascience Group plc (AIM: OXP), the specialty pharmaceutical ...
01/14/16 10:02 AMInitiation of Pilot Clinical Study - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ('Oxford Pharmascience' or the 'Company') for Reduced Gastro-Intestinal Irritation Ibuprofen Oxford Pharmascience Group plc (AIM: OXP), the ...
01/14/16 10:02 AMInitiation of Pilot Clinical Study for Ibuprofen - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ('Oxford Pharmascience' or the 'Company') Initiation of Pilot Clinical Study for Reduced Gastro-Intestinal Irritation Ibuprofen Oxford Pharmascience ...
01/14/16 10:02 AMResults from Pilot Clinical Study of OXP500 - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ('Oxford Pharmascience' or the 'Company') Encouraging Results from Pilot Clinical Study of OXPzero TM Naproxen (OXP005) Oxford Pharmascience, ...
01/14/16 10:02 AMPreliminary PK Data & Initiation of Further Study - [at noodls] - Oxford Pharmascience Group PLC Oxford Pharmascience Group plc ('Oxford Pharmascience' or the 'Company') Preliminary Pharmacokinetic Data and Initiation of Pilot Clinical Study to Demonstrate Improved GI ...

Social

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc logoOxford Pharmascience Group plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in re-developing medicines. The Company engages in research and development activities based around its core technology platforms and focuses on commercializing the related products to pharmaceutical organizations. The Company's pipeline is focused on pain relief and cardiovascular disease indications. The Company's pipeline includes Ibuprofen, Naproxen, Diclofenac and Aspirin. Its nonsteroidal anti-inflammatory drug (NSAID) clinical development program involves re-developing NSAIDs to make them milder in the gastrointestinal (GI) tract and mask the typical NSAID taste/burn. The Company's SafeStat clinical development program includes developing statins platform. The Company's OXPzero Technology releases the drug in its molecular ionized form, reducing localized concentration.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: OXP
  • CUSIP:
Key Metrics:
  • Previous Close: $0.04
  • 50 Day Moving Average: $5.20
  • 200 Day Moving Average: $5.23
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $39.18M
  • Current Year EPS Consensus Estimate: $N/A EPS
  • Next Year EPS Consensus Estimate: $N/A EPS
Additional Links: